Enzelo 25000mg Capsule contains Pancreatin, a combination of digestive enzymes including amylase, lipase, and protease, each contributing to the breakdown of carbohydrates, fats, and proteins respectively. This medication is primarily indicated for patients with pancreatic exocrine insufficiency due to conditions such as chronic pancreatitis, cystic fibrosis, pancreatic surgery, or other disorders resulting in impaired digestion. By supplementing endogenous enzymes, Enzelo facilitates improved digestion and absorption of nutrients, thereby alleviating symptoms such as steatorrhea, malnutrition, and weight loss associated with enzyme deficiency. The recommended dosage should be individualized based on the severity of enzyme insufficiency and dietary fat content, and it is typically administered orally with meals or snacks to optimize enzymatic activity. Patients should be advised to swallow the capsules whole without crushing or chewing to prevent inactivation of enzymes and potential irritation of the oral mucosa. Common adverse effects are generally mild and may include gastrointestinal discomfort, nausea, or allergic reactions. Enzelo is contraindicated in patients with hypersensitivity to pancreatin or any component of the formulation. Caution is advised in individuals with acute pancreatitis or pancreatic carcinoma. Proper medical supervision is essential to monitor therapeutic efficacy and adjust dosing as required.